Liquid Biopsy Market Global Report 2020-30 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global liquid biopsy market.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the liquid biopsy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Liquid Biopsy market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider liquid biopsy market, and compares it with other markets.
Scope
Markets Covered: 1) By Product: Assays Kits; Instruments; Services; 2) By End User: Reference Laboratories; Hospitals and Physician Laboratories; Academic and Research Centers; 3) By Clinical Application: Early Cancer Screening; Therapy Selection; Treatment Monitoring; Recurrence Monitoring Orthopedics
Companies Mentioned: QIAGEN N.V.; Roche Diagnostics; Bio-Rad Laboratories Inc.; Myriad Genetics, Inc.; Guardant Health Inc.
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:
Where is the largest and fastest growing market for the liquid biopsy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Liquid Biopsy market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider liquid biopsy market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
- The liquid biopsy market section of the report gives context. It compares the liquid biopsy market with other segments of the liquid biopsy market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, liquid biopsy indicators comparison.
Scope
Markets Covered: 1) By Product: Assays Kits; Instruments; Services; 2) By End User: Reference Laboratories; Hospitals and Physician Laboratories; Academic and Research Centers; 3) By Clinical Application: Early Cancer Screening; Therapy Selection; Treatment Monitoring; Recurrence Monitoring Orthopedics
Companies Mentioned: QIAGEN N.V.; Roche Diagnostics; Bio-Rad Laboratories Inc.; Myriad Genetics, Inc.; Guardant Health Inc.
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1. Executive Summary2. Liquid Biopsy Market Characteristics26. Key Mergers And Acquisitions In The Liquid Biopsy Market27. Liquid Biopsy Market Trends And Strategies28. Liquid Biopsy Market Future Outlook and Potential Analysis
3. Liquid Biopsy Market Size And Growth
4. Liquid Biopsy Market Segmentation
5. Liquid Biopsy Market Regional And Country Analysis
6. Asia-Pacific Liquid Biopsy Market
7. China Liquid Biopsy Market
8. India Liquid Biopsy Market
9. Japan Liquid Biopsy Market
10. Australia Liquid Biopsy Market
11. Indonesia Liquid Biopsy Market
12. South Korea Liquid Biopsy Market
13. Western Europe Liquid Biopsy Market
14. UK Liquid Biopsy Market
15. Germany Liquid Biopsy Market
16. France Liquid Biopsy Market
17. Eastern Europe Liquid Biopsy Market
18. Russia Liquid Biopsy Market
19. North America Liquid Biopsy Market
20. USA Liquid Biopsy Market
21. South America Liquid Biopsy Market
22. Brazil Liquid Biopsy Market
23. Middle East Liquid Biopsy Market
24. Africa Liquid Biopsy Market
25. Liquid Biopsy Market Competitive Landscape And Company Profiles
29. Appendix
Executive Summary
The liquid biopsy market consists of sales of liquid biopsy services and related products used to detect cancer at an early stage. Liquid biopsy is an easy and minimally invasive technology which involves test done on a blood sample to detect the DNA from tumour cells in the blood. Unlike surgical biopsies it allows medical doctors to find a tumour through a blood test. The liquid biopsy helps in planning further treatment for cancer.The global liquid biopsy market was worth $2.9 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 20.80% and reach $6.1 billion by 2023.
The liquid biopsy market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. North America was the largest region in 2019 and Asia-Pacific is expected to grow fastest in the forecast period.
The liquid biopsy market covered in this report is segmented by product into assays kits, instruments, services. It is also segmented by end user into reference laboratories, hospitals and physician laboratories, academic and research centres and by clinical application into early cancer screening, therapy selection, treatment monitoring, recurrence monitoring orthopedics.
Government funds for refining cancer detection drives the growth of the liquid biopsy market. Government funds helps researchers in drug discovery, diagnosis, and treatment of diseases such as Cancer. For instance, in 2019, National Cancer Institute (NCI), a USA-based government agency gave funds worth $2.1 million and a five-year grant to Translational Genomics Research Institute (TGen), a genomics research institute based in U.S.A. The funding enables TGen and Mayo Clinic researchers to drive the clinical trials for liquid biopsy test for the detection of breast cancer. Also, in 2017, the German Federal Ministry of Education and Research raised a fund amount of €500,000 ($531,615) to CeGaT, a German genetic testing firm. The funding was done to support the research and development of liquid biopsy methods used for the analysis of circulating tumor DNA. Therefore, government funds positively impact the growth of liquid biopsy market.
Unclear regulations on laboratory developed tests (LDT) for liquid biopsy have always been a major challenge in the liquid biopsy market. A laboratory developed test (LDT) is an in-vitro diagnostic test (IVD) intended for clinical use that is designed, manufactured to be used in a single laboratory. For instance, in 2019, the Food and Drug Administration (FDA) proposed a plan to increase the regulations for the approval of laboratory developed tests. However, the regulations are unclear and do not reduce the time it takes for the approval of these tests. Following this, the FDA, till 2019, has approved only two liquid biopsy tests. The first test which identifies EGFR mutations in NSCLC patients was approved in 2016 while the second test for detecting the PIK3CA mutation in patients was approved in 2019. Such delays in the approval of liquid biopsy tests by the FDA are expected to have a negative impact on the liquid biopsy market.
Companies are rapidly adopting new market dynamics and focusing primarily on new product launches, to meet the ever-increasing need for liquid biopsy products and services, to increase their revenue and also for gaining a competitive edge over their rivals. For instance, in 2017, QIAGEN N.V., a Germany based provider of sample and assay technologies for molecular diagnostics broadened its pipeline in liquid biopsy by launching AdnaTest Prostate Cancer Panel AR-V7. This panel is used for detecting androgen receptor splice variant 7 from liquid biopsies for investigating resistance in new medicines for advanced prostate cancer. The AdnaTest provides a significant biomarker for clinical research to provide for the future development of the diagnosis of prostate cancer by providing precise insights from tumor cells in blood samples. Thus, companies are investing in the development of new products in the liquid biopsy market.
In October 2018, Precision for Medicine, a part of the Precision Medicine Group, acquired Apo-Cell for an undisclosed amount. The acquisition adds ApoCell’s expertise in tissue genomic profiling and liquid biopsy technology to Precision for Medicine. Precision Medicine Group is a US-based pharmaceutical company involved in the development and commercialization of drugs. ApoCell, Inc., is a US-based lab involved in the identification and analysis of customized biomarker solutions.
Major players in the market are QIAGEN N.V., Roche Diagnostics, Bio-Rad Laboratories Inc., Myriad Genetics, Inc., Guardant Health Inc., Thermo Fisher Scientific, Guardant Health, Menarini Silicon Biosystems, Biocept, Inc. and F. Hoffmann-La Roche AG.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- QIAGEN N.V.
- Roche Diagnostics
- Bio-Rad Laboratories Inc.
- Myriad Genetics, Inc.
- Guardant Health Inc.
- Thermo Fisher Scientific
- Guardant Health
- Menarini Silicon Biosystems
- Biocept, Inc.
- F. Hoffmann-La Roche AG
- Janssen Diagnostics, LLC.
- Tr0vagene Inc.
- Fraunhofer-Gesellschaft
- MDX Health SA
- Agilent Technologies Inc.
- Cygnus Biosciences
- Illumina Inc.
- Oxford Nanopore
- Quantum Biosystems
Methodology
LOADING...
